about
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.MET and ALK as targets for the treatment of NSCLC.Targeting the MET gene for the treatment of non-small-cell lung cancer.MET and Small-Cell Lung Cancer.Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?FGFR as potential target in the treatment of squamous non small cell lung cancer.Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer.Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review.First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements.A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event.Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC.Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.Immune-mediated cholangitis: is it always nivolumab's fault?Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumabNivolumab-induced cholangitic liver disease: a novel form of serious liver injuryAccuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung CancerFatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancerComplete recalcification following arterial embolization of massive osteolytic bone metastasis from non-small cell lung cancer (NSCLC)Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutationsDo we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancerResistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancerThe circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLCArterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected FindingPhase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
P50
Q33892582-BAC19A48-43A3-4EC2-9FC7-D3D9F2EF4F21Q37952233-66B5D4F2-D560-45D1-8329-F5D9B3D39370Q37952236-516CA983-3F12-4052-8C0D-000AAD939BB0Q38153827-F3DA4D6D-1FC8-4AEB-A6CF-57441B0DEEF1Q38172700-A557F471-32F5-4E12-B2A0-19C2F1775DB6Q38260120-E04F0A35-EAAB-464E-BD4F-CE786BE37C16Q38293725-4D2E98FF-DD8C-4FD1-B6AE-9623FF6EC888Q38435145-AB996AC8-42D6-4302-84C2-E745B55A2651Q38470406-392FE87C-2D4E-4D5A-BB4F-C5BEDB1DCBC1Q38640845-A7CE0F5A-D334-461E-A2B4-152723415C26Q38841082-27A20F17-E76F-4B61-81D2-7718160A519BQ38863105-0A2C4EEF-2EF4-4515-8636-B9FF6E971481Q38996107-1BD206BE-FC9D-4AAD-B825-A580B19B11D1Q39009124-2E942E3B-3713-44E9-B0B8-904EF5A4B65BQ39013047-968869D6-2A6F-45A8-9557-867A79175B72Q39384997-34A60965-F50A-4FE4-A1AD-83D6943F76CCQ44407561-E94B06BA-27CF-43DC-9D96-FF9CA443EFB2Q50140953-0FE77391-5858-449A-A849-209BF99E68CDQ52983636-C6C3AD4F-C2E9-405C-B8EC-39EDDE6C144BQ54582444-C47F8EE2-4015-47BE-A416-3768C59DE562Q56352164-C6C0CD8B-D8EA-44CF-8B9B-ED5BD1217538Q56380345-31A573D9-DDA3-439B-A0A6-FC16759D565AQ56960955-5E97C4CA-F666-442E-8EF0-25D944EE9E39Q57762661-104CF4E3-DEAE-4CF4-B0B2-F9FCF049509FQ57763406-5F9FE502-E691-47D7-893F-B304C7AE7B13Q58586458-2807B8B4-4DC8-4DCE-A9E6-E24DA98C82FBQ62661790-B8D998BF-6631-4FE2-A600-DA0FE0A9AAF3Q87227033-93A5EE68-CD8E-4B16-AA4B-3E34EA76987EQ90345439-91E99C99-0AAD-4500-BCE2-B47F0267415EQ90352700-4D5B87B0-3972-4339-BEAB-389BED383C6DQ91043026-963C2025-877C-407E-9F50-B7648070F7D2Q93357527-359E6EEE-0416-4FAE-9D4B-C4CC5D94F2F7Q94452299-1FF5E500-3961-45B9-B927-AF24FE268960
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesco Gelsomino
@ast
Francesco Gelsomino
@en
Francesco Gelsomino
@es
Francesco Gelsomino
@nl
Francesco Gelsomino
@sl
type
label
Francesco Gelsomino
@ast
Francesco Gelsomino
@en
Francesco Gelsomino
@es
Francesco Gelsomino
@nl
Francesco Gelsomino
@sl
prefLabel
Francesco Gelsomino
@ast
Francesco Gelsomino
@en
Francesco Gelsomino
@es
Francesco Gelsomino
@nl
Francesco Gelsomino
@sl
P106
P21
P31
P496
0000-0002-9204-1728